Biogen (NASDAQ:BIIB) Upgraded at Argus

Argus upgraded shares of Biogen (NASDAQ:BIIB) from a hold rating to a buy rating in a research report sent to investors on Thursday morning, MarketBeat.com reports. They currently have $280.00 target price on the biotechnology company’s stock.

A number of other research analysts also recently commented on BIIB. Jefferies Financial Group reiterated a “buy” rating on shares of Biogen in a research report on Monday, July 13th. Wells Fargo & Company boosted their price target on shares of Biogen from $250.00 to $310.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 20th. Bank of America upped their price target on shares of Biogen from $219.00 to $244.00 and gave the company a “neutral” rating in a research note on Thursday, October 22nd. Robert W. Baird increased their price objective on shares of Biogen from $250.00 to $290.00 and gave the company an “outperform” rating in a research report on Thursday. Finally, UBS Group lifted their price objective on shares of Biogen from $240.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Biogen has an average rating of “Moderate Buy” and an average price target of $251.00.

Biogen Stock Performance

Shares of NASDAQ BIIB opened at $253.62 on Thursday. The company has a market cap of $37.49 billion, a P/E ratio of 108.38, a P/E/G ratio of 2.97 and a beta of 0.09. Biogen has a 52-week low of $146.52 and a 52-week high of $258.78. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.95. The firm’s fifty day moving average is $227.08 and its two-hundred day moving average is $201.04.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Wednesday, October 28th. The biotechnology company reported $2.62 EPS for the quarter, beating the consensus estimate of $1.99 by $0.63. The business had revenue of $2.80 billion during the quarter, compared to the consensus estimate of $2.63 billion. Biogen had a net margin of 3.37% and a return on equity of 9.38%. The business’s revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $4.81 EPS. As a group, analysts anticipate that Biogen will post 12.44 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. 3Chopt Investment Partners LLC acquired a new stake in Biogen in the third quarter worth about $204,000. Compass Financial Management LLC raised its position in Biogen by 1,029,900.0% during the third quarter. Compass Financial Management LLC now owns 10,300 shares of the biotechnology company’s stock valued at $2,327,000 after acquiring an additional 10,299 shares in the last quarter. Rakuten Investment Management Inc. increased its holdings in shares of Biogen by 10.0% during the 3rd quarter. Rakuten Investment Management Inc. now owns 26,512 shares of the biotechnology company’s stock valued at $6,020,000 after purchasing an additional 2,415 shares in the last quarter. Provenance Wealth Advisors LLC purchased a new position in Biogen in the 3rd quarter worth approximately $29,000. Finally, Lyell Wealth Management LP purchased a new position in Biogen during the third quarter worth approximately $209,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Better-than-expected Q3 results: Biogen reported adjusted earnings of $2.62 per share, above the $1.99 consensus estimate, while revenue reached $2.80 billion versus expectations of $2.63 billion. Revenue increased 10.6% year over year, supporting the view that the company is returning to growth. Biogen Reaches New 1-Year High on Better-Than-Expected Earnings
• Positive Sentiment: Analysts raised targets following the earnings beat: UBS lifted its target to $300, while Baird and Needham raised theirs to $290. Argus upgraded Biogen from “hold” to “buy” with a $280 target; RBC increased its target to $272 and retained an outperform rating. Canaccord Genuity also raised its target to $272 and assigned a buy rating. Analysts Increase Their Forecasts on Biogen After Upbeat Q3 Results
• Positive Sentiment: Growth narrative is improving: RBC analysts said Biogen’s quarterly performance suggests a growth-led comeback, potentially sustaining investor momentum after a period of declining results. Biogen Swings Back to Growth as Stock Momentum Could Continue
• Positive Sentiment: Alzheimer’s pipeline catalyst: Biogen plans to present long-term and real-world data at the November CTAD conference, including five-year Clarity AD extension data for lecanemab and additional Phase 2 CELIA data for diranersen. Positive results could strengthen confidence in the company’s Alzheimer’s portfolio and future growth prospects. Biogen to Present New Data Across Alzheimer’s Disease Portfolio at CTAD 2026
• Neutral Sentiment: Mixed analyst valuation signals: TD Cowen and Truist raised targets to $260, but those imply only modest upside from the current level. The concentration of target increases after earnings is supportive, although expectations are now higher.
• Negative Sentiment: Morgan Stanley remains cautious: The firm raised its target to $238 but kept an “equal weight” rating, indicating potential downside if Biogen’s growth recovery or pipeline data disappoints.

Biogen Company Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.